Study DesignGo to
interesting timing of patent approval with study completion date iminent
Study Type: Interventional (Clinical Trial) 1 ActualEnrollment: 88 participants 2 Allocation: Randomized 3 Intervention Model: Parallel Assignment 4 Masking: None (Open Label) 5 Primary Purpose: Treatment 6 Official Title: A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer 7 ActualStudy Start Date: July 2, 2018 8 ActualPrimary Completion Date: February 27, 2020 9 EstimatedStudy Completion Date: August 31, 2021
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-12
- There are more pages in this discussion • 732 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
43.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $511.1M |
Open | High | Low | Value | Volume |
43.0¢ | 43.5¢ | 40.5¢ | $1.728M | 4.071M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7170 | 42.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.0¢ | 217563 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8996 | 0.470 |
1 | 3000 | 0.415 |
3 | 30000 | 0.410 |
3 | 124000 | 0.405 |
9 | 139000 | 0.400 |
Price($) | Vol. | No. |
---|---|---|
0.425 | 2040 | 1 |
0.430 | 51803 | 2 |
0.435 | 104673 | 2 |
0.440 | 147000 | 5 |
0.445 | 23000 | 3 |
Last trade - 16.10pm 11/06/2024 (20 minute delay) ? |
|
|||||
Last
42.0¢ |
  |
Change
0.000 ( 2.28 %) |
|||
Open | High | Low | Volume | ||
42.5¢ | 43.0¢ | 40.5¢ | 1272184 | ||
Last updated 15.59pm 11/06/2024 ? |
Featured News
IMM (ASX) Chart |